AveXis, Inc.: Diferență între versiuni
Admin (discuție | contribuții) (Pagină nouă: Pagina dedicata companiei AveXis, Inc. listata cu simbolul US.AVXS ==Descriere companie== Novartis Gene Therapies, Inc. (https://www.novartis.com/), a gene therapy biotech company, develops treatments for rare and life-threatening genetic diseases. The company focuses on developing gene therapy product candidates for the treatment of type 1 spinal muscular atrophy, an autosomal-recessive genetic disorder characterized by lower motor neuron loss and progressive muscle weaknes...) |
(The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).) |
||
| Linia 2: | Linia 2: | ||
==Descriere companie== | ==Descriere companie== | ||
Novartis Gene Therapies, Inc. (https://www.novartis.com/), a gene therapy biotech company, develops treatments for rare and life-threatening genetic diseases. The company focuses on developing gene therapy product candidates for the treatment of type 1 spinal muscular atrophy, an autosomal-recessive genetic disorder characterized by lower motor neuron loss and progressive muscle weakness. It offers AVXS-101, a AveXis’ gene therapy for the treatment of spinal muscular atrophy SMA Type 1, which is in Phase 1 clinical trial. Novartis Gene Therapies, Inc. was formerly known as AveXis, Inc., and changed its name in September 2020. The company was founded in 2010 and is based in Bannockburn, Illinois. AveXis, Inc. operates as a subsidiary of Novartis AG. | Novartis Gene Therapies, Inc. (https://www.novartis.com/), a gene therapy biotech company, develops treatments for rare and life-threatening genetic diseases. The company focuses on developing gene therapy product candidates for the treatment of type 1 spinal muscular atrophy, an autosomal-recessive genetic disorder characterized by lower motor neuron loss and progressive muscle weakness. It offers AVXS-101, a AveXis’ gene therapy for the treatment of spinal muscular atrophy SMA Type 1, which is in Phase 1 clinical trial. Novartis Gene Therapies, Inc. was formerly known as AveXis, Inc., and changed its name in September 2020. The company was founded in 2010 and is based in Bannockburn, Illinois. AveXis, Inc. operates as a subsidiary of [[Novartis AG]]. | ||
==Grafic actiuni companie== | ==Grafic actiuni companie== | ||
Versiunea curentă din 29 septembrie 2024 12:20
Pagina dedicata companiei AveXis, Inc. listata cu simbolul US.AVXS
Descriere companie[edit | ]
Novartis Gene Therapies, Inc. (https://www.novartis.com/), a gene therapy biotech company, develops treatments for rare and life-threatening genetic diseases. The company focuses on developing gene therapy product candidates for the treatment of type 1 spinal muscular atrophy, an autosomal-recessive genetic disorder characterized by lower motor neuron loss and progressive muscle weakness. It offers AVXS-101, a AveXis’ gene therapy for the treatment of spinal muscular atrophy SMA Type 1, which is in Phase 1 clinical trial. Novartis Gene Therapies, Inc. was formerly known as AveXis, Inc., and changed its name in September 2020. The company was founded in 2010 and is based in Bannockburn, Illinois. AveXis, Inc. operates as a subsidiary of Novartis AG.
Grafic actiuni companie[edit | ]